Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The degree to which functional connectivity between brain regions is affected by the properties of white matter pathways is a fundamental question in neuroscience.

Magnetic resonance imaging can study both the strength of communication between brain regions (functional connectivity) and the properties of the pathways that connect them (white matter microstructure). Animal studies suggest that these things are related, but there is little literature on this in humans.

Jeroen Mollink, Karla Miller and Saad Jbabdi used 11,000 subjects from UK Biobank to ask whether features related to white matter microstructure (diffusion MRI) can predict the synchrony of functional MRI activity in the regions a given pathway connects.

They constructed models of diffusion MRI derived features to predict functional connectivity. 'One exciting finding is that that microstructure-function relationships are a general property of the brain', said lead author Jeroen Mollink, 'Our microstructure models were able to identify statistically significant variation in function in the vast majority - 90% - of brain regions we considered.'

The research revealed that these relationships are specific, in that you almost always get a better prediction if you use the correct white matter pathway for a given region, compared to predictions using a different white matter pathway. 

In addition, these relationships are reproducible. The researchers trained the models on an initial cohort of 7500 subjects, and then used them to predict functional connectivity in 3800 un-seen subjects.

Finally, the team discovered a unique genetic profile for these relatoinships, via a genome-wide association study of the function-microstructure prediction for each region

The identification of these small but reproducible effects can be a first step toward aggregate measures with greater explanatory power.

Read the full paper here

Similar stories

New Analysis Challenges Guidelines on Treating Anorexia Nervosa

Research Highlights

A new analysis, published in The Lancet Psychiatry, has shown a lack of strong evidence to support current guidance on psychological therapies for treating anorexia nervosa over expert treatment as usual.

Capturing immune cells that colonise the brain to prevent disease progression in multiple sclerosis

Research Highlights

Researchers have revealed a disease-causing population of immune cells, which travel to the brain in patients with multiple sclerosis. They demonstrate how to trap these cells in the blood, which means they can be targeted to prevent disease progression.

How the brain reorganises old memories when new ones are made

Research Highlights

Researchers have discovered that the arrangement of existing memories in the brain is altered when we embed new memories

Improving Experiences of People with Serious Mental Health Problems

Research Highlights

A project led by Professor Kam Bhui and Dr Roisin Mooney, University of Oxford, will focus on reducing the number of people admitted or readmitted to compulsory care under the Mental Health Act. This is one of four new research projects funded by the National Institute for Health Research (NIHR) with the aim to improve patient experiences and outcomes under the Mental Health Act.

Potential New Target to Prevent or Delay Dementia

Research Highlights

New study shows targeting arterial stiffening earlier in a person’s lifespan could provide cognitive benefits in older age and may help to delay the onset of dementia.

Investigating New Treatment for Schizophrenia

Research Highlights Strategic Developments

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim has been announced to investigate a new drug target for the treatment of schizophrenia.